1. Home
  2. RTX vs AZN Comparison

RTX vs AZN Comparison

Compare RTX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RTX Corporation

RTX

RTX Corporation

HOLD

Current Price

$172.65

Market Cap

271.3B

Sector

Industrials

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$188.29

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTX
AZN
Founded
1934
1992
Country
United States
United Kingdom
Employees
N/A
96100
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.3B
316.4B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
RTX
AZN
Price
$172.65
$188.29
Analyst Decision
Buy
Strong Buy
Analyst Count
12
1
Target Price
$204.25
N/A
AVG Volume (30 Days)
4.1M
1.8M
Earning Date
04-21-2026
04-29-2026
Dividend Yield
1.52%
1.66%
EPS Growth
39.72
N/A
EPS
1.51
N/A
Revenue
$80,738,000,000.00
N/A
Revenue This Year
$6.50
$10.34
Revenue Next Year
$6.71
$6.43
P/E Ratio
$118.77
$31.91
Revenue Growth
17.15
N/A
52 Week Low
$123.60
$66.16
52 Week High
$214.50
$212.71

Technical Indicators

Market Signals
Indicator
RTX
AZN
Relative Strength Index (RSI) 23.11 40.32
Support Level $166.74 $182.39
Resistance Level $180.66 $209.98
Average True Range (ATR) 5.10 3.24
MACD -2.62 -1.98
Stochastic Oscillator 0.59 7.52

Price Performance

Historical Comparison
RTX
AZN

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: